Private equity player Celtic bankrolls new Swiss antibody-drug conjugate company
This article was originally published in Scrip
Celtic Therapeutics Management, a global private equity firm focused on novel therapeutic product candidates, is leveraging the power of a technology platform owned by portfolio company Spirogen to create a new company focused on antibody drug conjugate (ADC) products. Alongside other Spirogen shareholders, Celtic Therapeutics is earmarking up to $50million for Lausanne, Switzerland-based ADC Therapeutics to develop a pipeline of 10 proprietary antibody drug conjugate oncology development programmes, targeting multiple major cancers, including prostate, renal, breast, lung and blood cancers.
You may also be interested in...
The company extended its series E financing to $276m to keep its two lead ADC candidates moving toward pivotal data and BLA filings, including a planned filing for ADCT-402 late next year. The funding news comes as the ADC field moves into the spotlight.
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.